Medical Research
(H80)
IRS Verified
DX Registered
990 on File
CDG CARE
Financial strength (30%)
92/100
Reliability (20%)
50/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
Find a cure for PMM2-CDG (Phosphomannomutase 2 deficiency) is a rare congenital disorder of glycosylation that affects multiple systems in the body.
Financial Overview — FY 2024
$531K
Total Revenue
$344K
Total Expenses
$709K
Net Assets
1
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
88.5%
Fundraising Efficiency
N/A
Operating Reserve
24.74x
Liability-to-Asset
1.0%
Revenue Diversification
94.5%
Executive Compensation
$13K
Compared with Peers
FY 2024
Compared with 726 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
88.5% | 84.5% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
7.5% | 11.4% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
4.0% | 0.0% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
24.7 mo | 13.4 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
1.0% | 0.4% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
94.5% | 93.3% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
8.0% | 9.1% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-34.5% | 8.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
35.2% | 1.8% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $531K | $344K | $709K | 88.5% | 1 |
| 2023 | $492K | $526K | $523K | 99.7% | 0 |
| 2022 | $715K | $397K | $598K | 99.1% | 0 |
| 2021 | $532K | $126K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.